The Obesity Drug Game of $ 870 million of Eli Lilly could turn the market, will it be the next $ 1T stock?
Indianapolis, in -Le Lilly (NYSE: LLY), an important player in the rapid weight weight loss drug market, has signed an important license agreement with the Swedish Biotechnology Company Camurus to improve the way in which their medications for obesity are delivered. The agreement gives Lilly access to Camurus fluidcrycrycrycrycrycrycrycrrystal®, which allows medications to be slowly…